ГЕНЕТИЧЕСКИЕ АСПЕКТЫ ТЯЖЕСТИ ТЕЧЕНИЯ COVID-19-ИНФЕКЦИИ. ОБЗОР
Аннотация
Течение COVID-19-инфекции варьирует в широких пределах, включая в большинстве случаев бессимптомное неосложненное течение до развития умеренных и тяжелых симптомов заболевания, вплоть до летальных исходов. Риск тяжелого течения COVID-19-инфекции связан со многими факторами, и в том числе обусловлен генетическими особенностями организма. В данном обзоре рассматриваются генетические аспекты риска и восприимчивости к тяжелому течению COVID-19-инфекции по последним данным литературы.
Литература
Глотов О.С., Чернов А.Н., Щербак С.Г., Баранов В.С. Генетические факторы риска развития коронавирусной инфекции COVID-19. Russ. J. Genet. 2021; 57: 878–92. https://doi.org/10.1134/S1022795421080056.
Aung A.K., Aitken T., Teh B.M. et al. Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study. J Infect. 2020; 81(6): 961–5. DOI: 10.1016/j.jinf.2020.11.012. Epub 2020 Nov 14. PMID: 33197472; PMCID: PMC7666537.
Anzurez A., Naka I., Miki S. et al. Association of HLA-DRB1*09:01 with severe COVID-19. HLA. 2021; 98(1): 37–42. DOI: 10.1111/tan.14256. Epub 2021 Apr 13. PMID: 33734601; PMCID: PMC8251239.
Agwa S.H.A., Kamel M.M., Elghazaly H. et al. Association between Interferon-Lambda-3 rs12979860, TLL1 rs17047200 and DDR1 rs4618569 variant polymorphisms with the course and outcome of SARS-CoV-2 patients. Genes. 2021; 12: 830. https://doi.org/10.3390/genes12060830.
Asselta R., Paraboschi E.M., Mantovani A., Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY). 2020; 12(11): 10087–98. DOI: 10.18632/aging.103415. Epub 2020 Jun 5. PMID: 32501810; PMCID: PMC7346072.
Booth A., Reed A.B., Ponzo S. et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and metaanalysis.PLoSOne. 2021; 16(3): e0247461. DOI:10.1371/journal.pone.0247461. PMID: 33661992; PMCID: PMC7932512.
Verma S., Abbas M., Verma S. et al. Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients. Infect Genet Evol. 2021; 91: 104801. DOI: 10.1016/j.meegid.2021.104801. Epub 2021 Mar 4. PMID: 33676010; PMCID: PMC7929788.
Ben Shachar S., Barda N., Manor S. et al. MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population. J Clin Immunol. 2021; 41(6): 1154–61. DOI: 10.1007/s10875-021-01071-x.
Cafiero C., Rosapepe F., Palmirotta R. et al. Angiotensin System Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study. Pharmgenomics Pers Med. 2021; 14: 621–9. DOI: 10.2147/PGPM.S303666. PMID: 34079337; PMCID: PMC8166347.
Casanova J.L., Su H.C. COVID Human Genetic Effort. A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell. 2020; 181(6): 1194–9. DOI: 10.1016/j.cell.2020.05.016. Epub 2020 May 13. PMID: 32405102; PMCID: PMC7218368.
Cascella M., Rajnik M., Aleem A. et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2023 Jan 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023; PMID: 32150360.
Calabrese C., Annunziata A., Coppola A. et al. ACE Gene I/D Polymorphism and Acute Pulmonary Embolism in COVID19 Pneumonia: A Potential Predisposing Role. Front Med (Lausanne). 2021; 7: 631148. DOI: 10.3389/fmed.2020.631148. PMID: 33585520; PMCID: PMC7874110.
Darbeheshti F., Mahdiannasser M., Uhal B.D. et al. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus. Rev Med Virol. 2021; 31(6): e2234. DOI: 10.1002/rmv.2234. Epub 2021 Mar 16. PMID: 33724604; PMCID: PMC8250219.
D'Amico S., Tempora P., Lucarini V. et al. ERAP1 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19? Int J Mol Sci. 2021; 22(4): 1705. DOI: 10.3390/ijms22041705. PMID: 33567739; PMCID: PMC7914632.
Delanghe J.R., De Buyzere M.L., Speeckaert M.M. Genetic Polymorphisms in the Host and COVID-19 Infection. Adv Exp Med Biol. 2021; 1318: 109–18. DOI: 10.1007/978-3-030-63761-3_7. PMID: 33973175.
Ebrahimi S., Ghasemi-Basir H.R., Majzoobi M.M. et al. HLA-DRB1*04 may predict the severity of disease in a group of Iranian COVID-19 patients. Hum Immunol. 2021; 82(10): 719–25. DOI: 10.1016/j.humimm.2021.07.004. Epub 2021 Jul 13. PMID: 34294460; PMCID: PMC8275473.
Fernandez C., Rysä J., Almgren P. et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018; 284(4): 377–87. DOI: 10.1111/joim.12783. Epub 2018 Jul 2. PMID: 29888466; PMCID: PMC6175079.
Grimaudo S., Amodio E., Pipitone R.M. et al.
PNPLA3 and TLL-1 Polymorphisms as Potential Predictors of Disease Severity in Patients With COVID-19. Front Cell Dev Biol. 2021; 9: 627914. DOI: 10.3389/fcell.2021.627914. PMID: 34249902; PMCID: PMC8262646.
Goel R.R., Cotenko C., Caplan M. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 2021; 17: 349–62. https://doi. org/10.1038/s41584-021-00606-1.
Giammaria D., Pajewski A. Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic? J Glob Health. 2020; 10(1): 010377. DOI: 10.7189/jogh.10.010377. PMID: 32582439; PMCID: PMC7307801.
Hashemi S.M.A., Thijssen M., Hosseini S.Y. et al. Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. Arch Virol. 2021; 166(8): 2089–2108. DOI: 10.1007/s00705-021-05070-6. Epub 2021 May 2. PMID: 33934196; PMCID: PMC8088757.
Hossein Teimouri H., Maali A. Single-Nucleotide Polymorphisms in Host Pattern-Recognition Receptors Show Association with Antiviral Responses against SARS-CoV-2, in-silico Trial. J Med Microbiol Infect Dis, 2020; 8 (2): 65–70. DOI: 10.29252/JoMMID.8.2.65.
Hovhannisyan A., Madelian V., Avagyan S. et al. HLA-C*04:01 Affects HLA Class I Heterozygosity and Predicted Affinity to SARS-CoV-2 Peptides, and in Combination With Age and Sex of Armenian Patients Contributes to COVID-19 Severity. Front Immunol. 2022; 13: 769900. DOI: 10.3389/fimmu.2022.769900. PMID: 35185875; PMCID: PMC8850920.
Ishak A., Mehendale M., AlRawashdeh M.M. et al. The association of COVID-19 severity and susceptibility and genetic risk factors: A systematic review of the literature.Gene. 2022; 836: 146674. DOI: 10.1016/j.gene.2022.146674. Epub 2022 Jun 14. PMID: 35714803; PMCID: PMC9195407.
Iyer G.R., Samajder S., Zubeda S. et al. Infectivity and Progression of COVID-19 Based on Selected Host Candidate Gene Variants. Front Genet. 2020; 11: 861. DOI: 10.3389/fgene.2020.00861. PMID: 33101356; PMCID: PMC7500201.
Jin J.J., Nakura J., Wu Z. et al. Association of angiotensin II type 2 receptor gene variant with hypertension. Hypertens Res. 2003; 26(7): 547–52. DOI: 10.1291/hypres.26.547. PMID: 12924622.
Karakaş Çelik S., Çakmak Genç G., Pişkin N. et al. Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: A case study. J Med Virol. 2021; 93(10): 5947–52. DOI: 10.1002/jmv.27160. Epub 2021 Jul 10. PMID: 34170561; PMCID: PMC8426884.
Kotenko S.V., Gallagher G., Baurin V.V. et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003; 4(1): 69–77. DOI: 10.1038/ni875. Epub 2002 Dec 16. PMID: 12483210.
Kousathanas A., Pairo-Castineira E., Rawlik K. et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature. 2022; 607(7917): 97–103. DOI: 10.1038/s41586-022-04576-6. Epub 2022 Mar 7. PMID: 35255492; PMCID: PMC9259496.
Latini A., Agolini E., Novelli A. et al. COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells. Genes (Basel). 2020; 11(9): 1010. DOI: 10.3390/genes11091010. PMID: 32867305; PMCID: PMC7565048.
Langton D.J., Bourke S.C., Lie B.A. et al. The influence of HLA genotype on the severity of COVID-19 infection. HLA. 2021; 98(1): 14–22. DOI: 10.1111/tan.14284. Epub 2021 May 4. PMID: 33896121; PMCID: PMC8251294.
Lorente L., Martín M.M., Franco A. et al. Working Group on COVID-19 Canary ICU; Annex. Members of the BIOMEPOC group. HLA genetic polymorphisms and prognosis of patients with COVID-19. Med Intensiva (Engl Ed). 2021; 45(2): 96–103. DOI: 10.1016/j.medin.2020.08.004. Epub 2020 Sep 6. PMID: 32988645; PMCID: PMC7905376.
Lim K.H., Staudt L.M. Toll-like receptor signaling. Cold Spring Harb Perspect Biol. 2013; 5(1): a011247. DOI: 10.1101/cshperspect.a011247. PMID: 23284045; PMCID: PMC3579400.
Littera R., Campagna M., Deidda S. et al. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Front Immunol. 2020; 11: 605688. DOI: 10.3389/fimmu.2020.605688. PMID: 33343579; PMCID: PMC7746644.
Mahmood Z.S., Fadhil H.Y., Abdul Hussein T.A., Ad'hiah A.H. Severity of coronavirus disease 19: Profile of inflammatory markers and ACE (rs4646994) and ACE2 (rs2285666) gene polymorphisms in Iraqi patients. Meta Gene. 2022; 31: 101014. DOI: 10.1016/j.mgene.2022.101014. Epub 2022 Jan 10. PMID: 35036327; PMCID: PMC8744396.
Mathur R., Rentsch C.T., Morton C.E. et al. OpenSAFELY Collaborative. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021; 397(10286): 1711–24. DOI: 10.1016/S0140-6736(21)00634-6. Epub 2021 Apr 30. Erratum in: Lancet. 2021. PMID: 33939953; PMCID: PMC8087292.
Millett G.A., Jones A.T., Benkeser D., Baral S., Mercer L., Beyrer C., Honermann B., Lankiewicz E., Mena L., Crowley J.S., Sherwood J., Sullivan P.S. Assessing differential impacts of COVID-19 on black communities. Ann Epidemiol. 2020 ;47:37-44. DOI: 10.1016/j.annepidem.2020.05.003. Epub 2020 May 14. PMID: 32419766; PMCID: PMC7224670.
Ma F., Yang Y., Li X. et al. The association of sport performance with ACE and ACTN3 genetic polymorphisms: a systematic review and meta-analysis. PLoS One. 2013; 8(1): e54685. DOI: 10.1371/journal.pone.0054685. Epub 2013 Jan 24. PMID: 23358679; PMCID: PMC3554644.
Muniyappa R., Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020; 318(5): E736–41. DOI: 10.1152/ajpendo.00124.2020. Epub 2020 Mar 31. PMID: 32228322; PMCID: PMC7191633.
Ned R.M., Yesupriya A., Imperatore G. et al. The ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity. Am J Hypertens. 2012; 25(2): 209–15. DOI: 10.1038/ajh.2011.182. Epub 2011 Oct 13. PMID: 21993364.
Pisanti S., Deelen J., Gallina A.M. et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Transl Med. 2020; 18(1): 352.
DOI: 10.1186/s12967-020-02515-5. PMID: 32933522; PMCID: PMC7491019.
Palacios Y., Ruiz A., Ramón-Luing L.A. et al. Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality. Int J Mol Sci. 2021; 22(16): 8423. DOI: 10.3390/ijms22168423. PMID: 34445140; PMCID: PMC8395100.
Rahimi P., Tarharoudi R., Rahimpour A. et al. The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients. Virol J. 2021; 18(1): 221. DOI: 10.1186/s12985-021-01692-z. PMID: 34775984; PMCID: PMC8590865.
Russo R., Andolfo I., Lasorsa V.A. et al. The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy. Genes (Basel). 2021; 12(6): 881. DOI: 10.3390/genes12060881. PMID: 34201032; PMCID: PMC8226789.
Saad H., Jabotian K., Sakr C. et al. The Role of Angiotensin Converting Enzyme 1 Insertion/Deletion Genetic Polymorphism in the Risk and Severity of COVID-19 Infection. Front Med (Lausanne). 2021; 8: 798571. DOI: 10.3389/fmed.2021.798571. PMID: 35004773; PMCID: PMC8733297.
Sabater Molina M., Nicolás Rocamora E., Bendicho A.I. et al. Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease. PLoS One. 2022; 17(2): e0263140. DOI: 10.1371/journal.pone.0263140. PMID: 35120165; PMCID: PMC8815985.
Srivastava A., Bandopadhyay A., Das D. et al. Genetic Association of ACE2 rs2285666 Polymorphism With COVID-19 Spatial Distribution in India. Front Genet. 2020; 11: 564741. DOI: 10.3389/fgene.2020.564741. PMID: 33101387; PMCID: PMC7545580.
Sieron L., Lesiak M., Schisler I. et al. Functional and structural studies of tolloid-like 1 mutants associated with atrial-septal defect 6. Biosci Rep. 2019; 39(1): BSR20180270. DOI: 10.1042/BSR20180270. PMID: 30538173; PMCID: PMC6328869.
Smulski C.R., Eibel H. BAFF and BAFF-Receptor in B Cell Selection and Survival. Front Immunol. 2018; 9: 2285. DOI: 10.3389/fimmu.2018.02285. PMID: 30349534; PMCID: PMC6186824.
Takeda M. Proteolytic activation of SARS-CoV-2 spike protein. Microbiol Immunol. 2022; 66(1): 15–23. DOI: 10.1111/1348-0421.12945. Epub 2021 Oct 12. PMID: 34561887; PMCID: PMC8652499.
Tomita Y., Ikeda T., Sato R., Sakagami T. Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis. Immun Inflamm Dis. 2020; 8(4): 684–94. DOI: 10.1002/iid3.358. Epub 2020 Oct 13. PMID: 33047883; PMCID: PMC7654404.
Weiner J., Suwalski P., Holtgrewe M. et al. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021; 40: 101099. DOI: 10.1016/j.eclinm.2021.101099. Epub 2021 Sep 2. PMID: 34490415; PMCID: PMC8410317.
https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019.
https://ru.wikipedia.org/wiki.
Yamamoto N., Ariumi Y., Nishida N. et al. SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype. Gene. 2020; 758: 144944. DOI: 10.1016/j.gene.2020.144944. Epub 2020 Jul 3. PMID: 32628976; PMCID: PMC7833925.
Yildirim Z., Sahin O.S., Yazar S., Bozok Cetintas V. Genetic and epigenetic factors associated with increased severity of Covid-19. Cell Biol Int. 2021; 45(6): 1158–74. DOI: 10.1002/cbin.11572. Epub 2021 Mar 1. PMID: 33590936; PMCID: PMC8014716.
Yung Y.L., Cheng C.K., Chan H.Y. et al. Association of HLA-B22 serotype with SARS-CoV-2 susceptibility in Hong Kong Chinese patients. HLA. 2021; 97(2): 127–32. DOI: 10.1111/tan.14135. Epub 2020 Dec 1. PMID: 33179437; PMCID: PMC7898481.
Zheng M., Karki R., Williams E.P. et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021; 22(7): 829–38. DOI: 10.1038/s41590-021-00937-x. Epub 2021 May 7. PMID: 33963333; PMCID: PMC8882317.
The COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. European Journal of Human Genetics. 2020; 28: 715–8. https://doi.org/10.1038/s41431-020-0636-6.
REFERENCES
Glotov O.S., Chernov A.N., Shcherbak S.G., Baranov V.S. Geneticheskie faktory riska razvitiya koronavirusnoy infektsii COVID-19. [Genetic risk factors for the development of coronavirus infection COVID-19]. Zhurnal genetika. 2021; 57: 878–92. (in Russian).
Aung A.K., Aitken T., Teh B.M. et al. Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study. J Infect. 2020; 81(6): 961–5. DOI: 10.1016/j.jinf.2020.11.012. Epub 2020 Nov 14. PMID: 33197472; PMCID: PMC7666537.
Anzurez A., Naka I., Miki S. et al. Association of HLA-DRB1*09:01 with severe COVID-19. HLA. 2021; 98(1): 37–42. DOI: 10.1111/tan.14256. Epub 2021 Apr 13. PMID: 33734601; PMCID: PMC8251239.
Agwa S.H.A., Kamel M.M., Elghazaly H. et al. Association between Interferon-Lambda-3 rs12979860, TLL1 rs17047200 and DDR1 rs4618569 variant polymorphisms with the course and outcome of SARS-CoV-2 patients. Genes. 2021; 12: 830. https://doi.org/10.3390/genes12060830.
Asselta R., Paraboschi E.M., Mantovani A., Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY). 2020; 12(11): 10087–98. DOI: 10.18632/aging.103415. Epub 2020 Jun 5. PMID: 32501810; PMCID: PMC7346072.
Booth A., Reed A.B., Ponzo S. et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and metaanalysis.PLoSOne. 2021; 16(3): e0247461. DOI: 10.1371/journal.pone.0247461. PMID: 33661992; PMCID: PMC7932512.
Verma S., Abbas M., Verma S. et al. Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients. Infect Genet Evol. 2021; 91: 104801. DOI: 10.1016/j.meegid.2021.104801. Epub 2021 Mar 4. PMID: 33676010; PMCID: PMC7929788.
Ben Shachar S., Barda N., Manor S. et al. MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population. J Clin Immunol. 2021; 41(6): 1154–61. DOI: 10.1007/s10875-021-01071-x.
Cafiero C., Rosapepe F., Palmirotta R. et al. Angiotensin System Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study. Pharmgenomics Pers Med. 2021; 14: 621–9. DOI: 10.2147/PGPM.S303666. PMID: 34079337; PMCID: PMC8166347.
Casanova J.L., Su H.C. COVID Human Genetic Effort. A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell. 2020; 181(6): 1194–9. DOI: 10.1016/j.cell.2020.05.016. Epub 2020 May 13. PMID: 32405102; PMCID: PMC7218368.
Cascella M., Rajnik M., Aleem A. et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2023 Jan 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023; PMID: 32150360.
Calabrese C., Annunziata A., Coppola A. et al. ACE Gene I/D Polymorphism and Acute Pulmonary Embolism in COVID19 Pneumonia: A Potential Predisposing Role. Front Med (Lausanne). 2021; 7: 631148. DOI: 10.3389/fmed.2020.631148. PMID: 33585520; PMCID: PMC7874110.
Darbeheshti F., Mahdiannasser M., Uhal B.D. et al. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus. Rev Med Virol. 2021; 31(6): e2234. DOI: 10.1002/rmv.2234. Epub 2021 Mar 16. PMID: 33724604; PMCID: PMC8250219.
D'Amico S., Tempora P., Lucarini V. et al. ERAP1 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19? Int J Mol Sci. 2021; 22(4): 1705. DOI: 10.3390/ijms22041705. PMID: 33567739; PMCID: PMC7914632.
Delanghe J.R., De Buyzere M.L., Speeckaert M.M. Genetic Polymorphisms in the Host and COVID-19 Infection. Adv Exp Med Biol. 2021; 1318: 109–18. DOI: 10.1007/978-3-030-63761-3_7. PMID: 33973175.
Ebrahimi S., Ghasemi-Basir H.R., Majzoobi M.M. et al. HLA-DRB1*04 may predict the severity of disease in a group of Iranian COVID-19 patients. Hum Immunol. 2021; 82(10): 719–25. DOI: 10.1016/j.humimm.2021.07.004. Epub 2021 Jul 13. PMID: 34294460; PMCID: PMC8275473.
Fernandez C., Rysä J., Almgren P. et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018; 284(4): 377–87. DOI: 10.1111/joim.12783. Epub 2018 Jul 2. PMID: 29888466; PMCID: PMC6175079.
Grimaudo S., Amodio E., Pipitone R.M. et al. PNPLA3 and TLL-1 Polymorphisms as Potential Predictors of Disease Severity in Patients With COVID-19. Front Cell Dev Biol. 2021; 9: 627914. DOI: 10.3389/fcell.2021.627914. PMID: 34249902; PMCID: PMC8262646.
Goel R.R., Cotenko C., Caplan M. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 2021; 17: 349–62. https://doi. org/10.1038/s41584-021-00606-1.
Giammaria D., Pajewski A. Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic? J Glob Health. 2020; 10(1): 010377. DOI: 10.7189/jogh.10.010377. PMID: 32582439; PMCID: PMC7307801.
Hashemi S.M.A., Thijssen M., Hosseini S.Y. et al. Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. Arch Virol. 2021; 166(8): 2089–2108. DOI: 10.1007/s00705-021-05070-6. Epub 2021 May 2. PMID: 33934196; PMCID: PMC8088757.
Hossein Teimouri H., Maali A. Single-Nucleotide Polymorphisms in Host Pattern-Recognition Receptors Show Association with Antiviral Responses against SARS-CoV-2, in-silico Trial. J Med Microbiol Infect Dis, 2020; 8 (2): 65–70. DOI: 10.29252/JoMMID.8.2.65.
Hovhannisyan A., Madelian V., Avagyan S. et al. HLA-C*04:01 Affects HLA Class I Heterozygosity and Predicted Affinity to SARS-CoV-2 Peptides, and in Combination With Age and Sex of Armenian Patients Contributes to COVID-19 Severity. Front Immunol. 2022; 13: 769900. DOI: 10.3389/fimmu.2022.769900. PMID: 35185875; PMCID: PMC8850920.
Ishak A., Mehendale M., AlRawashdeh M.M. et al. The association of COVID-19 severity and susceptibility and genetic risk factors: A systematic review of the literature.Gene. 2022; 836: 146674. DOI: 10.1016/j.gene.2022.146674. Epub 2022 Jun 14. PMID: 35714803; PMCID: PMC9195407.
Iyer G.R., Samajder S., Zubeda S. et al. Infectivity and Progression of COVID-19 Based on Selected Host Candidate Gene Variants. Front Genet. 2020; 11: 861. DOI: 10.3389/fgene.2020.00861. PMID: 33101356; PMCID: PMC7500201.
Jin J.J., Nakura J., Wu Z. et al. Association of angiotensin II type 2 receptor gene variant with hypertension. Hypertens Res. 2003; 26(7): 547–52. DOI: 10.1291/hypres.26.547. PMID: 12924622.
Karakaş Çelik S., Çakmak Genç G., Pişkin N. et al. Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: A case study. J Med Virol. 2021; 93(10): 5947–52. DOI: 10.1002/jmv.27160. Epub 2021 Jul 10. PMID: 34170561; PMCID: PMC8426884.
Kotenko S.V., Gallagher G., Baurin V.V. et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003; 4(1): 69–77. DOI: 10.1038/ni875. Epub 2002 Dec 16. PMID: 12483210.
Kousathanas A., Pairo-Castineira E., Rawlik K. et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature. 2022; 607(7917): 97–103. DOI: 10.1038/s41586-022-04576-6. Epub 2022 Mar 7. PMID: 35255492; PMCID: PMC9259496.
Latini A., Agolini E., Novelli A. et al. COVID-19 and Genetic Variants of Protein Involved in the
SARS-CoV-2 Entry into the Host Cells. Genes (Basel). 2020; 11(9): 1010. DOI: 10.3390/genes11091010. PMID: 32867305; PMCID: PMC7565048.
Langton D.J., Bourke S.C., Lie B.A. et al. The influence of HLA genotype on the severity of COVID-19 infection. HLA. 2021; 98(1): 14–22. DOI: 10.1111/tan.14284. Epub 2021 May 4. PMID: 33896121;
PMCID: PMC8251294.
Lorente L., Martín M.M., Franco A. et al. Working Group on COVID-19 Canary ICU; Annex. Members of the BIOMEPOC group. HLA genetic polymorphisms and prognosis of patients with COVID-19. Med Intensiva (Engl Ed). 2021; 45(2): 96–103. DOI: 10.1016/j.medin.2020.08.004. Epub 2020 Sep 6. PMID: 32988645; PMCID: PMC7905376.
Lim K.H., Staudt L.M. Toll-like receptor signaling. Cold Spring Harb Perspect Biol. 2013; 5(1): a011247. DOI: 10.1101/cshperspect.a011247. PMID: 23284045; PMCID: PMC3579400.
Littera R., Campagna M., Deidda S. et al. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Front Immunol. 2020; 11: 605688. DOI: 10.3389/fimmu.2020.605688. PMID: 33343579; PMCID: PMC7746644.
Mahmood Z.S., Fadhil H.Y., Abdul Hussein T.A., Ad'hiah A.H. Severity of coronavirus disease 19: Profile of inflammatory markers and ACE (rs4646994) and ACE2 (rs2285666) gene polymorphisms in Iraqi patients. Meta Gene. 2022; 31: 101014. DOI: 10.1016/j.mgene.2022.101014. Epub 2022 Jan 10. PMID: 35036327; PMCID: PMC8744396.
Mathur R., Rentsch C.T., Morton C.E. et al. OpenSAFELY Collaborative. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021; 397(10286): 1711–24. DOI: 10.1016/S0140-6736(21)00634-6. Epub 2021 Apr 30. Erratum in: Lancet. 2021. PMID: 33939953; PMCID: PMC8087292.
Millett G.A., Jones A.T., Benkeser D., Baral S., Mercer L., Beyrer C., Honermann B., Lankiewicz E., Mena L., Crowley J.S., Sherwood J., Sullivan P.S. Assessing differential impacts of COVID-19 on black communities. Ann Epidemiol. 2020 ;47:37-44. DOI: 10.1016/j.annepidem.2020.05.003. Epub 2020 May 14. PMID: 32419766; PMCID: PMC7224670.
Ma F., Yang Y., Li X. et al. The association of sport performance with ACE and ACTN3 genetic polymorphisms: a systematic review and meta-analysis. PLoS One. 2013; 8(1): e54685. DOI: 10.1371/journal.pone.0054685. Epub 2013 Jan 24. PMID: 23358679; PMCID: PMC3554644.
Muniyappa R., Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020; 318(5): E736–41. DOI: 10.1152/ajpendo.00124.2020. Epub 2020 Mar 31. PMID: 32228322; PMCID: PMC7191633.
Ned R.M., Yesupriya A., Imperatore G. et al. The
ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity. Am J Hypertens. 2012; 25(2): 209–15. DOI: 10.1038/ajh.2011.182. Epub 2011 Oct 13. PMID: 21993364.
Pisanti S., Deelen J., Gallina A.M. et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Transl Med. 2020; 18(1): 352. DOI: 10.1186/s12967-020-02515-5. PMID: 32933522;
PMCID: PMC7491019.
Palacios Y., Ruiz A., Ramón-Luing L.A. et al. Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality. Int J Mol Sci. 2021; 22(16): 8423. DOI: 10.3390/ijms22168423. PMID: 34445140; PMCID: PMC8395100.
Rahimi P., Tarharoudi R., Rahimpour A. et al. The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients. Virol J. 2021; 18(1): 221.
DOI: 10.1186/s12985-021-01692-z. PMID: 34775984;
PMCID: PMC8590865.
Russo R., Andolfo I., Lasorsa V.A. et al. The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy. Genes (Basel). 2021; 12(6): 881. DOI: 10.3390/genes12060881. PMID: 34201032; PMCID: PMC8226789.
Saad H., Jabotian K., Sakr C. et al. The Role of Angiotensin Converting Enzyme 1 Insertion/Deletion Genetic Polymorphism in the Risk and Severity of COVID-19 Infection. Front Med (Lausanne). 2021; 8: 798571. DOI: 10.3389/fmed.2021.798571. PMID: 35004773; PMCID: PMC8733297.
Sabater Molina M., Nicolás Rocamora E., Bendicho A.I. et al. Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease. PLoS One. 2022; 17(2): e0263140. DOI: 10.1371/journal.pone.0263140. PMID: 35120165; PMCID: PMC8815985.
Srivastava A., Bandopadhyay A., Das D. et al. Genetic Association of ACE2 rs2285666 Polymorphism With COVID-19 Spatial Distribution in India. Front Genet. 2020; 11: 564741. DOI: 10.3389/fgene.2020.564741. PMID: 33101387; PMCID: PMC7545580.
Sieron L., Lesiak M., Schisler I. et al. Functional and structural studies of tolloid-like 1 mutants associated with atrial-septal defect 6. Biosci Rep. 2019; 39(1): BSR20180270. DOI: 10.1042/BSR20180270. PMID: 30538173; PMCID: PMC6328869.
Smulski C.R., Eibel H. BAFF and BAFF-Receptor in B Cell Selection and Survival. Front Immunol. 2018; 9: 2285. DOI: 10.3389/fimmu.2018.02285. PMID: 30349534; PMCID: PMC6186824.
Takeda M. Proteolytic activation of SARS-CoV-2 spike protein. Microbiol Immunol. 2022; 66(1): 15–23. DOI: 10.1111/1348-0421.12945. Epub 2021 Oct 12. PMID: 34561887; PMCID: PMC8652499.
Tomita Y., Ikeda T., Sato R., Sakagami T. Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis. Immun Inflamm Dis. 2020; 8(4): 684–94. DOI: 10.1002/iid3.358. Epub 2020 Oct 13. PMID: 33047883; PMCID: PMC7654404.
Weiner J., Suwalski P., Holtgrewe M. et al. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021; 40: 101099. DOI: 10.1016/j.eclinm.2021.101099. Epub 2021 Sep 2. PMID: 34490415; PMCID: PMC8410317.
https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019.
https://ru.wikipedia.org/wiki.
Yamamoto N., Ariumi Y., Nishida N. et al. SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype. Gene. 2020; 758: 144944. DOI: 10.1016/j.gene.2020.144944. Epub 2020 Jul 3. PMID: 32628976; PMCID: PMC7833925.
Yildirim Z., Sahin O.S., Yazar S., Bozok Cetintas V. Genetic and epigenetic factors associated with increased severity of Covid-19. Cell Biol Int. 2021; 45(6): 1158–74. DOI: 10.1002/cbin.11572. Epub 2021 Mar 1. PMID: 33590936; PMCID: PMC8014716.
Yung Y.L., Cheng C.K., Chan H.Y. et al. Association of HLA-B22 serotype with SARS-CoV-2 susceptibility in Hong Kong Chinese patients. HLA. 2021; 97(2): 127–32. DOI: 10.1111/tan.14135. Epub 2020 Dec 1. PMID: 33179437; PMCID: PMC7898481.
Zheng M., Karki R., Williams E.P. et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021; 22(7): 829–38. DOI: 10.1038/s41590-021-00937-x. Epub 2021 May 7. PMID: 33963333; PMCID: PMC8882317.
The COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. European Journal of Human Genetics. 2020; 28: 715–8. https://doi.org/10.1038/s41431-020-0636-6.
